ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541

Rang în acțiuni #18992
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Preț acțiune
$0.4004091
Capitalizare de piață
$167.79M
Schimbare (1 zi)
5.39%
Schimbare (1 an)
-70.11%
Țară
CN
Tranzacționează ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)

Categorie

Healthcare
Istoricul spliturilor pentru ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Acțiunea ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (simbol: 1541) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 21, 2026.
O acțiune 1541 cumpărată înainte de Oct 21, 2026 este echivalentă astăzi cu 0 acțiuni 1541.
Listă splituri acțiuni
An Split Multiplu Multiplu cumulativ
Nu sunt suficiente date pentru perioada selectată.
Splituri pentru companii similare sau competitori
Companie Număr total de splituri Multiplu cumulativ Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH